Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. The company is headquartered in South San Francisco, California and currently employs 9 full-time employees. The company went IPO on 2018-06-21. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The firm is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Dr. Christopher Kirk is the Chief Executive Officer of Kezar Life Sciences Inc, joining the firm since 2015.
What is the price performance of KZR stock?
The current price of KZR is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Kezar Life Sciences Inc?
Kezar Life Sciences Inc belongs to Biotechnology industry and the sector is Health Care
What is Kezar Life Sciences Inc market cap?
Kezar Life Sciences Inc's current market cap is $NaN
Is Kezar Life Sciences Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Kezar Life Sciences Inc, including 3 strong buy, 3 buy, 4 hold, 0 sell, and 3 strong sell